Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer

NCT00005645 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00005645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 1999
Completion date
Not reported
Enrollment
0 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, metastatic cancer, ovarian cancer, primary peritoneal cavity cancer